+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PD-1 & PD-L1 Inhibitors Market by Product Type (PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Head and Neck Cancer, Lung Cancer), End User, Distribution Channel, Route Of Administration, Company - Global Forecast 2025-2030- Product Image
PD-1 & PD-L1 Inhibitors Market by Product Type (PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Head and Neck Cancer, Lung Cancer), End User, Distribution Channel, Route Of Administration, Company - Global Forecast 2025-2030- Product Image
Sale

PD-1 & PD-L1 Inhibitors Market by Product Type (PD-1 Inhibitor, PD-L1 Inhibitor), Indication (Bladder Cancer, Head and Neck Cancer, Lung Cancer), End User, Distribution Channel, Route Of Administration, Company - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674438
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The PD-1 & PD-L1 Inhibitors Market is redefining treatment paradigms in oncology, driven by advances in immuno-oncology and the shift toward precision, targeted therapies. As clinical adoption broadens, understanding this market’s complexities becomes essential for senior leadership seeking to leverage emerging trends, risk mitigation strategies, and operational advantages for business growth.

Market Snapshot: PD-1 & PD-L1 Inhibitors Market

The PD-1 & PD-L1 Inhibitors Market grew from USD 44.61 billion in 2024 to USD 53.91 billion in 2025. It is expected to continue growing at a CAGR of 20.69%, reaching USD 137.93 billion by 2030. Senior decision-makers will find this trajectory indicative of continued demand, fueled by expanding indications, improving diagnostics, and scalable manufacturing. Persistent innovation and evolving regulatory milestones are shaping how businesses position their portfolios, invest in R&D, and respond to the competitive landscape in immunotherapy.

Scope & Segmentation

This comprehensive report delivers actionable insight by delving into the critical market segments, key regions, relevant technologies, and major industry players influencing the PD-1 & PD-L1 inhibitor space:

  • Product Types: Cemiplimab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
  • Indications: Bladder Cancer, Head and Neck Cancer, Lung Cancer, Melanoma, Renal Cell Carcinoma
  • End Users: Hospitals, Research Institutes, Specialty Clinics
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Routes of Administration: Intravenous, Subcutaneous
  • Companies: AstraZeneca, Bristol-Myers Squibb, Merck & Co., Roche, Merck KGaA, Pfizer Inc., BeiGene, Innovent Biologics, CStone Pharmaceuticals, Shanghai Junshi Biosciences
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including United Kingdom, Germany, France, Russia, Middle East, Africa), Asia-Pacific (including China, India, Japan, Australia, South Korea, Southeast Asia)

Coverage includes recent developments in combination regimens, diagnostic tools, and emerging bioprocessing technologies supporting precision immuno-oncology therapies.

Key Takeaways for Decision-Makers

  • Checkpoint inhibitors are transitioning oncology from broad-spectrum chemotherapy to patient-specific, biomarker-guided therapeutics.
  • Ongoing digital health adoption, including AI imaging and remote patient monitoring, is streamlining patient recruitment, optimizing trial efficiency, and supporting value-based care.
  • Manufacturing innovations—such as continuous processing and modular production—are enhancing supply chain resilience and reducing operational risk.
  • Leading companies are differentiating through robust R&D pipelines, strategic partnerships, and expansion into new cancer indications and administration routes.
  • Regional market nuances, such as local pricing pressures and evolving reimbursement approaches in Asia-Pacific and EMEA, are informing tailored go-to-market strategies.
  • Collaborative initiatives with academic, technology, and industry partners are accelerating innovation and fostering long-term market sustainability.

Tariff Impact: Strategic Response to US Tariff Adjustments

Recent tariff changes in the United States have increased costs for globally sourced biologics components. In response, manufacturers are diversifying supply chains, partnering with domestic suppliers, and deploying decentralized manufacturing units closer to end-user markets. These strategies are designed to mitigate cost pressures and maintain continuity of patient access while reinforcing long-term operational flexibility for manufacturers navigating fluctuating trade policies.

Methodology & Data Sources

This analysis combines peer-reviewed literature, clinical registry and regulatory database reviews, public financial filings, and targeted interviews with oncologists, regulatory experts, supply chain specialists, and payer representatives. Data triangulation and rigorous validation ensure accurate, market-relevant insights spanning all major geographies and therapeutic areas.

Why This Report Matters

  • Equip leadership with a clear understanding of strategic shifts, competitive movements, and innovation drivers across the immunotherapy value chain.
  • Identify region-specific opportunities and risks to support targeted resource allocation, informed investment decisions, and scalable market entry.
  • Leverage actionable recommendations aligned with evolving regulatory standards, technological breakthroughs, and industry best practices.

Conclusion

This report empowers senior stakeholders to navigate and capture value in the evolving PD-1 & PD-L1 Inhibitors Market. Built on robust analytics, it delivers the intelligence needed to drive strategic growth, optimize clinical positioning, and improve patient care in oncology.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging bispecific antibodies targeting PD-1 and additional immune checkpoints to overcome resistance mechanisms
5.2. Increasing adoption of PD-1/PD-L1 inhibitors in earlier cancer treatment lines and adjuvant therapy settings to improve patient survival outcomes
5.3. Advancements in predictive biomarkers and companion diagnostics to optimize patient selection for PD-1/PD-L1 therapies
5.4. Combination regimens involving PD-1/PD-L1 inhibitors with novel targeted therapies and chemotherapy in solid tumors to enhance efficacy
5.5. Development of next generation PD-1/PD-L1 inhibitors featuring improved safety profiles and reduced immune-related adverse events in clinical trials
5.6. Expanding therapeutic indications for PD-1/PD-L1 inhibitors in rare cancers and non-oncology autoimmune conditions to broaden patient access
5.7. Integration of real-world evidence and health economic analyses to support reimbursement decisions for PD-1/PD-L1 inhibitors across global markets
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PD-1 & PD-L1 Inhibitors Market, by Product Type
8.1. Introduction
8.2. PD-1 Inhibitor
8.2.1. Cemiplimab
8.2.2. Nivolumab
8.2.3. Pembrolizumab
8.3. PD-L1 Inhibitor
8.3.1. Atezolizumab
8.3.2. Avelumab
8.3.3. Durvalumab
9. PD-1 & PD-L1 Inhibitors Market, by Indication
9.1. Introduction
9.2. Bladder Cancer
9.3. Head And Neck Cancer
9.4. Lung Cancer
9.5. Melanoma
9.6. Renal Cell Carcinoma
10. PD-1 & PD-L1 Inhibitors Market, by End User
10.1. Introduction
10.2. Hospitals
10.3. Research Institutes
10.4. Specialty Clinics
11. PD-1 & PD-L1 Inhibitors Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. PD-1 & PD-L1 Inhibitors Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Subcutaneous
13. PD-1 & PD-L1 Inhibitors Market, by Company
13.1. Introduction
13.2. AstraZeneca
13.3. Bristol-Myers Squibb
13.4. Merck & Co.
13.5. Roche
14. Americas PD-1 & PD-L1 Inhibitors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa PD-1 & PD-L1 Inhibitors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific PD-1 & PD-L1 Inhibitors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Bristol-Myers Squibb Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. AstraZeneca PLC
17.3.5. Merck KGaA
17.3.6. Pfizer Inc.
17.3.7. BeiGene, Ltd.
17.3.8. Innovent Biologics, Inc.
17.3.9. CStone Pharmaceuticals
17.3.10. Shanghai Junshi Biosciences Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PD-1 & PD-L1 INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PD-1 & PD-L1 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PD-1 & PD-L1 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PD-1 & PD-L1 INHIBITORS MARKET: RESEARCHAI
FIGURE 28. PD-1 & PD-L1 INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 29. PD-1 & PD-L1 INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 30. PD-1 & PD-L1 INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PD-1 & PD-L1 INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ASTRAZENECA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY BRISTOL-MYERS SQUIBB, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY MERCK & CO., BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROCHE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 111. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 114. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 115. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 116. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 117. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 126. CANADA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 127. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 130. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 131. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 132. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 133. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 209. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 212. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 213. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 214. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 215. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 216. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 217. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 224. GERMANY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 225. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 228. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 229. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 230. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 231. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 232. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 233. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 240. FRANCE PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 257. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 260. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 261. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 262. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 263. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 265. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 272. ITALY PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 273. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 276. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 277. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 278. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 279. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 288. SPAIN PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PD-L1 INHIBITOR, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY COMPANY, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA PD-1 & PD-L1 INHIBITORS MARK

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PD-1 & PD-L1 Inhibitors market report include:
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck KGaA
  • Pfizer Inc.
  • BeiGene, Ltd.
  • Innovent Biologics, Inc.
  • CStone Pharmaceuticals
  • Shanghai Junshi Biosciences Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 53.91 Billion
Forecasted Market Value ( USD ) by 2030 $ 137.93 Billion
Compound Annual Growth Rate20.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

PD-1 and PD-L1 Inhibitors Market Report and Forecast 2025-2034 - Product Image

PD-1 and PD-L1 Inhibitors Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

PD-1 And PD-L1 Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 160 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Global Strategic Business Report - Product Image

PD-1 and PD-L1 Inhibitors - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025 - Product Image

PD-1 And PD-L1 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025 - Product Image

PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.